A Phase 3 interventional study of entecavir and adefovir in Hepatitis B and Chronic Disease, sponsored by Bristol-Myers Squibb. Completed at 24 sites in 8 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2010-08-10.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 41st largest by enrollment of the 61 interventional ones that give a count, is one of 2 that started in 2004, is one of 13 in phase 3, and was the 4th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Qing-Lei Zeng
Ages 3–6
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 33
First in 2001; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 109 across the 61 interventional studies. Of the 40 that completed or were terminated, 15 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 64 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 23 finished, 11 (48%) have results posted.
Among the 24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2004, is one of 11 in phase 3, and was the 4th registered.
Bristol-Myers Squibb’s Hepatitis B, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 24 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate antiviral activity and efficacy of entecavir (ETV) compared to adefovir in adults with chronic hepatitis B who have not been treated yet with an antiviral medicine.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
This study's enrollment of 69 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Browse Hepatitis B, Chronic studies →Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: entecavir
Drug: adefovir
Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12
Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 12, adjusted for baseline (Week 12 - baseline). A negative value = improvement.
Time frame: Baseline, Week 12
Change From Baseline in HBV DNA by PCR Assay at Week 48
Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 48, adjusted for baseline (Week 48 - Baseline). A negative value = improvement.
Time frame: Baseline, Week 48
Viral Load Undetectable (HBV DNA <300 Copies/mL)
Number of Subjects with HBV DNA \<300 copies/mL by Roche COBAS® Amplicor (limit of quantitation 300 copies/mL)
Time frame: Week 48
Alanine Aminotransferase (ALT) Normalization
Number of participants with ALT ≤ 1 x upper limit of normal (ULN)
Time frame: Week 48
HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Efficacy in Blocking Virus Production and de Novo Infections
The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε) and effectiveness of the study treatment in blocking de novo infection of susceptible cells (η). The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.
Time frame: Week 12
HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Viral Clearance Rate and Infected Cell Death Rate
The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the clearance rate of the free virus (c), the death rate of productively infected cells (δ), The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.
Time frame: Week 12
HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus
The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. An important derived parameter is the half-life of free virus (ie, the average amount of time for HBV particles in plasma to be reduced to half the initial level), calculated as 24\*ln(2)/c. The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.
Time frame: Week 12
HBV DNA Viral Kinetics - Spline Model
This analysis uses a 3-parameter piece-wise linear model and describes the biphasic decline in HBV DNA (measured by PCR assay) through Week 12. The 3 parameters are the values for the 2 slopes, describing the first and second phase declines, respectively, and the estimated HBV DNA at the knot (at day 10; the time point where the 2 phases join). The biphasic viral decay kinetics for each treatment were obtained using a spline fitting procedure to estimate the 3 parameters for each subject; these estimates were then averaged within each treatment group.
Time frame: Week 12
Summary of Safety - Most Frequent (> 10%) Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Deaths
AE=new untoward medical occurrence or worsening of pre-existing medical condition regardless of causal relationship to treatment. SAE=untoward medical occurrence that is life-threatening, a congenital anomaly/birth defect, or an important medical event, or results in death, inpatient hospitalization/prolongation of hospitalization, or persistent/significant disability. AE grades: mild (1), moderate (2), severe (3), life-threatening (4), death (5). ALT flare= \>2x baseline \& \>10x ULN up to end of therapy + 5 days. Hepatic SAE=SAEs consistent with worsening of hepatitis or hepatic decompensation.
Time frame: cumulative through the end of on-treatment observation as available at the time of the Week 48 dataset
Summary of Safety - Laboratory Abnormalities Reported as Clinical AEs
Laboratory abnormalities reported as clinical AEs
Time frame: Week 48
| Milestone | Entecavir | Adefovir |
|---|---|---|
| Started | 35 | 34 |
| As-randomized population | 35 | 34 |
| As-treated population | 36 | 33 |
| Completed | 33 | 33 |
| Not completed | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Relocated | 1 | 0 |
Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 12, adjusted for baseline (Week 12 - baseline). A negative value = improvement.
| log10 copies/mL | Entecavir | Adefovir |
|---|---|---|
| Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12 | -6.23 ± 0.247 | -4.52 ± 0.357 |
Antiviral efficacy, as measured by the mean reduction in serum HBV DNA levels by PCR (log10 copies/mL) at Week 48, adjusted for baseline (Week 48 - Baseline). A negative value = improvement.
| log10 c/mL | Entecavir | Adefovir |
|---|---|---|
| Change From Baseline in HBV DNA by PCR Assay at Week 48 | -7.28 ± 0.327 | -5.08 ± 0.455 |
Number of Subjects with HBV DNA \<300 copies/mL by Roche COBAS® Amplicor (limit of quantitation 300 copies/mL)
| Participants | Entecavir | Adefovir |
|---|---|---|
| Viral Load Undetectable (HBV DNA <300 Copies/mL) | 19 | 6 |
Number of participants with ALT ≤ 1 x upper limit of normal (ULN)
| participants | Entecavir | Adefovir |
|---|---|---|
| Alanine Aminotransferase (ALT) Normalization | 25 | 20 |
The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the effectiveness of the drug in blocking virus production from infected cells (efficacy, ε) and effectiveness of the study treatment in blocking de novo infection of susceptible cells (η). The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.
| percent effective | Entecavir | Adefovir |
|---|---|---|
| Efficacy in blocking virus production - ε | 99.87 | 99.46 |
| Effectiveness in blocking de novo infections - η | 6.07 | 5.87 |
The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. The model parameters of interest are the clearance rate of the free virus (c), the death rate of productively infected cells (δ), The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.
| per day | Entecavir | Adefovir |
|---|---|---|
| Viral Clearance - c | 1.70 | 0.91 |
| Infected cell death - δ | 0.08 | 0.04 |
The biphasic decline of HBV DNA is characterized via a 4-parameter exponential decay model previously published for HBV compounds. An important derived parameter is the half-life of free virus (ie, the average amount of time for HBV particles in plasma to be reduced to half the initial level), calculated as 24\*ln(2)/c. The model parameters reflect the biphasic pattern that is typically observed after initiation of antiviral therapy. Parameters were estimated for each subject separately and then averaged within each treatment group.
| hours | Entecavir | Adefovir |
|---|---|---|
| HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus | 14.52 | 32.46 |
This analysis uses a 3-parameter piece-wise linear model and describes the biphasic decline in HBV DNA (measured by PCR assay) through Week 12. The 3 parameters are the values for the 2 slopes, describing the first and second phase declines, respectively, and the estimated HBV DNA at the knot (at day 10; the time point where the 2 phases join). The biphasic viral decay kinetics for each treatment were obtained using a spline fitting procedure to estimate the 3 parameters for each subject; these estimates were then averaged within each treatment group.
| log10 copies/mL | Entecavir | Adefovir |
|---|---|---|
| First slope (first phase of viral decay) | -0.391 | -0.329 |
| Second slope (second phase of viral decay) | -0.034 | -0.024 |
AE=new untoward medical occurrence or worsening of pre-existing medical condition regardless of causal relationship to treatment. SAE=untoward medical occurrence that is life-threatening, a congenital anomaly/birth defect, or an important medical event, or results in death, inpatient hospitalization/prolongation of hospitalization, or persistent/significant disability. AE grades: mild (1), moderate (2), severe (3), life-threatening (4), death (5). ALT flare= \>2x baseline \& \>10x ULN up to end of therapy + 5 days. Hepatic SAE=SAEs consistent with worsening of hepatitis or hepatic decompensation.
| Participants | Entecavir | Adefovir |
|---|---|---|
| Death | 0 | 0 |
| Serious AE | 1 | 3 |
| Discontinuation due to AE | 0 | 1 |
| Malignant neoplasm | 0 | 0 |
| On Treatment: Any AE | 28 | 27 |
| On Treatment: Headache | 9 | 6 |
| On Treatment: Upper Respiratory Infection | 8 | 8 |
| On Treatment: Influenza | 6 | 4 |
| On Treatment: Nasopharyngitis | 4 | 6 |
| On Treatment: Pyrexia | 4 | 6 |
| On Treatment: Back Pain | 0 | 5 |
| On Treatment: Grade 3-4 AEs | 2 | 5 |
| ALT Flare | 0 | 1 |
| Hepatic SAE | 1 | 2 |
Laboratory abnormalities reported as clinical AEs
| Participants | Entecavir | Adefovir |
|---|---|---|
| ALT increased | 1 | 2 |
| Lipase increased | 1 | 2 |
| Blood phosphorus decreased | 0 | 1 |
| Liver function test abnormal | 0 | 1 |
| Platelet count decreased | 0 | 1 |
| Protein urine present | 0 | 1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADV 10 mg | — | 2/33 (6.1%) | 16/33 (48.5%) |
| ETV 0.5 mg | — | 1/36 (2.8%) | 17/36 (47.2%) |
| Event | ADV 10 mg | ETV 0.5 mg |
|---|---|---|
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 1/33 | 1/36 |
| RIB FRACTUREInjury, poisoning and procedural complications | 1/33 | 0/36 |
| Event | ADV 10 mg | ETV 0.5 mg |
|---|---|---|
| HEADACHENervous system disorders | 5/33 | 8/36 |
| COUGHRespiratory, thoracic and mediastinal disorders | 4/33 | 2/36 |
| INFLUENZAInfections and infestations | 2/33 | 4/36 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/33 | 4/36 |
| LIPASE INCREASEDInvestigations | 2/33 | 0/36 |
| DIZZINESSNervous system disorders | 2/33 | 0/36 |
| NASOPHARYNGITISInfections and infestations | 2/33 | 2/36 |
| BACK PAINMusculoskeletal and connective tissue disorders | 2/33 | 0/36 |
| RHINORRHOEARespiratory, thoracic and mediastinal disorders | 2/33 | 0/36 |
| MALAISEGeneral disorders | 2/33 | 0/36 |
| Age Continuous(years) | Entecavir | Adefovir | Total |
|---|---|---|---|
| Mean | 37 ± 2.3 | 32 ± 1.9 | 34 ± 1.5 |
| Age Continuous(participants) | Entecavir | Adefovir | Total |
|---|---|---|---|
| Median | 38 (18 to 76) | 28 (17 to 57) | 31 (17 to 76) |
| Sex: Female, Male(Participants) | Entecavir | Adefovir | Total |
|---|---|---|---|
| Female | 13 | 11 | 24 |
| Male | 22 | 23 | 45 |
| Race/Ethnicity, Customized(Participants) | Entecavir | Adefovir | Total |
|---|---|---|---|
| Asian | 31 | 30 | 61 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 3 | 2 | 5 |
| White | 1 | 1 | 2 |
| Region of Enrollment(participants) | Entecavir | Adefovir | Total |
|---|---|---|---|
| North America | 9 | 13 | 22 |
| East Asia | 26 | 21 | 47 |
| Prior interferon (IFN)(Participants) | Entecavir | Adefovir | Total |
|---|---|---|---|
| Prior IFN | 1 | 1 | 2 |
| No prior IFN | 34 | 33 | 67 |
| Alanine Aminotransferease (ALT)(U/L) | Entecavir | Adefovir | Total |
|---|---|---|---|
| Mean | 109.4 ± 81.76 | 176.4 ± 207.22 | 142.4 ± 159.12 |
| Hepatitis B virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR)(log10 copies/mL) | Entecavir | Adefovir | Total |
|---|---|---|---|
| Mean | 10.45 ± 2.125 | 9.89 ± 1.201 | 10.18 ± 1.742 |
The record gives a start of Dec 2004, a primary completion of Jan 2006 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Entecavir · Adefovir